CD58 and cancer: Since it was observed that CD58, the ligand for CD2, and CD112 and CD155, which function as ligands for CD226, are ubiquitously expressed in different cancer cell lines (Supplementary Figure 1A), we investigated whether introducing these molecules in our TCR-transgenic reporters will increase their sensitivity for their cognate antigens.